To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
ProImmune Launches CFSE T Cell Proliferation Assays for Assessing Drug Immunogenicity Risk
Read time: Less than a minute
ProImmune Ltd has launched CFSE T cell proliferation assays for immunogenicity risk assessment.
The assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.
Combined with ProImmune’s cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, these new assays enable the creation of a detailed profile of the helper T cell immune response to one or more drug leads.
Unlike traditional assays, which are based on radioactive thymidine incorporation, ProImmune’s new assays utilize flow cytometry methods, enabling determination of the percentage of proliferating CD4-positive cells and detailed phenotyping of T cell responses with improved overall sensitivity.
Dr. Nikolai Schwabe, CEO of ProImmune, said: "Our customers have come to expect ProImmune to deliver technology leadership without compromise. The launch of our CFSE T-cell proliferation assays joins with our unequalled capability in class II HLA binding assays, delivering the most powerful in vitro assay platform on the market for assessing drug immunogenicity risk.”
The assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.
Combined with ProImmune’s cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, these new assays enable the creation of a detailed profile of the helper T cell immune response to one or more drug leads.
Unlike traditional assays, which are based on radioactive thymidine incorporation, ProImmune’s new assays utilize flow cytometry methods, enabling determination of the percentage of proliferating CD4-positive cells and detailed phenotyping of T cell responses with improved overall sensitivity.
Dr. Nikolai Schwabe, CEO of ProImmune, said: "Our customers have come to expect ProImmune to deliver technology leadership without compromise. The launch of our CFSE T-cell proliferation assays joins with our unequalled capability in class II HLA binding assays, delivering the most powerful in vitro assay platform on the market for assessing drug immunogenicity risk.”
